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Statement of findings
The biologically active metabolite of vitamin D3, 1a,25-dihydroxyvitamin D3 [1a,25(OH)2D3],
acts through vitamin D receptors, which were found in rheumatoid tissues in the present
study. IL-1b-activated rheumatoid synovial fibroblasts and human articular chondrocytes
were shown to respond differently to exposure to 1a,25(OH)2D3, which has different effects
on the regulatory pathways of specific matrix metalloproteinases and prostaglandin E2.
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Introduction: 1a,25-dihydroxyvitamin D3 [1a,25(OH)2D3], the
biologically active metabolite of vitamin D3, acts through an
intracellular vitamin D receptor (VDR) and has several
immunostimulatory effects. Animal studies have shown that
production of some matrix metalloproteinases (MMPs) may be
upregulated in rat chondrocytes by administration of
1a,25(OH)2D3; and cell cultures have suggested that
1a,25(OH)2D3 may affect chondrocytic function.
Discoordinate regulation by vitamin D of MMP-1 and MMP-9 in
human mononuclear phagocytes has also been reported.
These data suggest that vitamin D may regulate MMP
expression in tissues where VDRs are expressed.
Production of 1a,25(OH)2D3 within synovial fluids of arthritic
joints has been shown and VDRs have been found in rheumatoid
synovial tissues and at sites of cartilage erosion. The
physiological function of 1a,25(OH)2D3 at these sites remains
obscure. MMPs play a major role in cartilage breakdown in the
rheumatoid joint and are produced locally by several cell types
under strict control by regulatory factors. As 1a,25(OH)2D3
modulates the production of specific MMPs and is produced
within the rheumatoid joint, the present study investigates its
effects on MMP and prostaglandin E2 (PGE2) production in two
cell types known to express chondrolytic enzymes.
Aims: To investigate VDR expression in rheumatoid tissues and to
examine the effects of 1a,25-dihydroxyvitamin D3 on cultured
rheumatoid synovial fibroblasts (RSFs) and human articular
chondrocytes (HACs) with respect to MMP and PGE2 production.
Methods: Rheumatoid synovial tissues were obtained from
arthroplasty procedures on patients with late-stage rheumatoid
arthritis; normal articular cartilage was obtained from lower limb
amputations. Samples were embedded in paraffin, and examined
for presence of VDRs by immunolocalisation using a biotinylated
antibody and alkaline-phosphatase-conjugated avidin–biotin
complex system. Cultured synovial fibroblasts and chondrocytes
were treated with either 1a,25(OH)2D3 or interleukin (IL)-1b, or
both. Conditioned medium was assayed for MMP and PGE2 by
enzyme-linked immunosorbent assay (ELISA), and the results
were normalised relative to control values.
Results: The rheumatoid synovial tissue specimens (n = 18)
immunostained for VDRs showed positive staining but at
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variable distributions and in no observable pattern. VDR-
positive cells were also observed in association with some
cartilage-pannus junctions (the rheumatoid lesion).
MMP production by RSFs in monolayer culture was not
affected by treatment with 1a,25(OH)2D3 alone, but when
added simultaneously with IL-1b the stimulation by IL-1b
was reduced from expected levels by up to 50%. In contrast,
1a,25(OH)2D3 had a slight stimulatory effect on basal
production of MMPs 1 and 3 by monolayer cultures of
HACs, but stimulation of MMP-1 by IL-1b was not affected
by the simultaneous addition of 1a,25(OH)2D3 whilst MMP-3
production was enhanced (Table 1). The production of
PGE2 by RSFs was unaffected by 1a,25(OH)2D3 addition,
but when added concomitantly with IL-1b the expected IL-
1b-stimulated increase was reduced to almost basal levels.
In contrast, IL-1b stimulation of PGE2 in HACs was not
affected by the simultaneous addition of 1a,25(OH)2D3
(Table 2). Pretreatment of RSFs with 1a,25(OH)2D3 for 1h
made no significant difference to IL-1b-induced stimulation
of PGE2, but incubation for 16h suppressed the expected
increase in PGE2 to control values. This effect was also
noted when 1a,25(OH)2D3 was removed after the 16h and
the IL-1b added alone. Thus it appears that 1a,25(OH)2D3
does not interfere with the IL-1b receptor, but reduces the
capacity of RSFs to elaborate PGE2 after IL-1b induction.
Discussion: Cells within the rheumatoid lesion which
expressed VDR were fibroblasts, macrophages, lymphocytes
and endothelial cells. These cells are thought to be involved
in the degradative processes associated with rheumatoid
arthritis (RA), thus providing evidence of a functional role of
1a,25(OH)2D3 in RA. MMPs may play important roles in the
chondrolytic processes of the rheumatoid lesion and are
known to be produced by both fibroblasts and
chondrocytes. The 1a,25(OH)2D3 had little effect on basal
MMP production by RSFs, although more pronounced
differences were noted when IL-1b-stimulated cells were
treated with 1a,25(OH)2D3, with the RSF and HAC showing
quite disparate responses. These opposite effects may be
relevant to the processes of joint destruction, especially
cartilage loss, as the ability of 1a,25(OH)2D3 to potentiate
MMP-1 and MMP-3 expression by ‘activated’ chondrocytes
might facilitate intrinsic cartilage chondrolysis in vivo. By
contrast, the MMP-suppressive effects observed for
1a,25(OH)2D3 treatment of ‘activated’ synovial fibroblasts
might reduce extrinsic chondrolysis and also matrix
degradation within the synovial tissue. Prostaglandins have a
role in the immune response and inflammatory processes
associated with RA. The 1a,25(OH)2D3 had little effect on
basal PGE2 production by RSF, but the enhanced PGE2
production observed following IL-1b stimulation of these
cells was markedly suppressed by the concomitant addition
of 1a,25(OH)2D3. As with MMP production, there are
disparate effects of 1a,25(OH)2D3 on IL-1b stimulated PGE2
production by the two cell types; 1a,25(OH)2D3 added
concomitantly with IL-1b had no effect on PGE2 production
by HACs. In summary, the presence of VDRs in the
rheumatoid lesion demonstrates that 1a,25(OH)2D3 may
have a functional role in the joint disease process.
1a,25(OH)2D3 does not appear to directly affect MMP or
PGE2 production but does modulate cytokine-induced
production.
Table 2
Comparative effects of 1a a,25-dihydroxyvitamin D3 (1a a,25D3) on
interleukin (IL)-1-stimulated prostaglandin E2 production by
rheumatoid synovial fibroblasts and human articular
chondrocytes in vivo
Fibroblasts Chondrocytes
Control 1 1
+ 1a,25D3 1.23 ± 0.16 1.35 ± 0.25
+ IL-1 7.07 ± 1.09 3.7 ± 1.05
+ IL-1 + 1a,25D3 1.61 ± 0.7 4.23 ± 1.10
Data given are normalized relative to control values and are expressed
± SEM for three cultures of each cell type.
Table 1
Comparative effects of 1a a,25-dihydroxyvitamin D3 (1a a,25D3) on interleukin (IL)-1-stimulated matrix metalloproteinase (MMP)-1 and
MMP-3 production by rheumatoid synovial fibroblasts and human articular chondrocytes in vivo
Fibroblasts Chondrocytes
MMP-1 MMP-3 MMP-1 MMP-3
Control 1 1 1 1
+ 1a,25D3 1.03 ± 0.27 2.07 ± 0.35 1.38 ± 0.19 1.59 ± 0.22
+ IL-1 31.09 ± 4.97 31.28 ± 8.49 3.45 ± 0.49 9.05 ±0.62
+ IL-1 + 1a,25D3 15.55 ± 5.86 11.84 ± 2.82 3.71 ± 0.53 11.11 ± 0.31
Data given are normalized relative to control values and are expressed ± SEM for three cultures of each cell type.65
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Introduction
The biologically active metabolite of vitamin D3, 1a,25-
dihydroxyvitaminD3 [1a,25(OH)2D3], acts through an intra-
cellular receptor [vitamin D receptor (VDR)] and has a
main role in the regulation of calcium and phosphorus
metabolism [1]. It also has several immunomodulatory
actions such as its effect on the differentiation and prolifera-
tion of T lymphocytes, and the regulation of immunoglobu-
lin production by B lymphocytes [2–4]. 1a,25(OH)2D3 may
affect chondrocytic function, such as proteoglycan and col-
lagen synthesis [5]; and animal studies have shown that the
production of some matrix metalloproteinases (MMPs),
namely interstitial collagenase (MMP-1), stromelysin
(MMP-3) and 72-kDa gelatinase (MMP-2), may be upregu-
lated in rat chondrocytes by administration of the metabo-
lite [6]. Discoordinate regulation by vitamin D of MMP-1
and MMP-9 in human mononuclear phagocytes has also
been reported [7]. Together these data have suggested that
vitamin D can regulate MMP expression in tissues or
pathologies where receptors for the hormone are expressed.
The kidney is recognized as the primary source of
1a,25(OH)2D3, producing the metabolite via 1-hydroxy-
lation of 25-hydroxyvitamin D3 [1]. However, the local
production of 1a,25(OH)2D3 within synovial fluids of
arthritic joints, especially the macrophage component, has
recently been indicated [8,9]; and receptors for vitamin D
have also been demonstrated in rheumatoid synovial
tissues and at sites of cartilage erosion [10]. Such studies
have demonstrated a local source of 1a,25(OH)2D3 within
the rheumatoid joint, but its regulation and physiological
functions at this site remain obscure.
MMPs are reputed to play a major role in cartilage break-
down in the rheumatoid joint and are produced locally by
several cell types, but especially by synovial fibroblasts
and articular chondrocytes [11–16]. MMP production and
release is microenvironmental in nature and is tightly
regulated by several factors, including the proinflamma-
tory cytokines tumour necrosis factor-a and interleukin
(IL)-1b [17]. Because 1a,25(OH)2D3 has been shown to
modulate the production of specific MMPs and is pro-
duced within the rheumatoid joint, the present study was
designed to investigate the effects of 1a,25(OH)2D3 on
MMP and prostaglandin E2 (PGE2) production by
rheumatoid synovial fibroblasts (RSFs) and human articu-
lar chondrocytes (HACs), cell types known to express
chondrolytic enzymes both in vitro and in vivo.
Methods
Tissue samples
Samples of rheumatoid synovial tissue, cartilage and carti-
lage–pannus junction were obtained from arthroplasty
procedures performed on patients with classic late-stage
rheumatoid arthritis. Normal articular cartilage samples were
obtained from lower limb amputations. Samples were fixed
in Carnoy’s fixative at 20°C for 2h, embedded in paraffin
wax and 5mm sections cut. Tissue sections were dewaxed,
rehydrated and examined for the presence of VDR. 
Immunolocalization of vitamin D receptors
Tissue sections were treated with 2N HCl at 37°C for
30min, this being the antigen retrieval procedure recom-
mended by the supplier of the primary antibody. Nonim-
mune rabbit serum at 10% (vol : vol) in TRIS-buffered
saline was applied to the sections for 20min at 20°C before
incubation with the primary antibody. Rat monoclonal anti-
body to chick VDR (Biogenex, San Remo, USA), which is
known to cross-react with human VDR, was applied to the
sections for 2h at 20°C after dilution 1:40 in TRIS-buffered
saline. After 3×10min washing in TRIS-buffered saline,
biotinylated rabbit anti-rat immunoglobulin G (DAKO,
Glostrup, Denmark) diluted 1:200 in TRIS-buffered saline
was applied to the sections for 45min at 20°C. After further
washing in TRIS-buffered saline, alkaline phosphatase-
conjugated ABC (Avidin–biotin complex system; DAKO)
was applied to the sections for 45min at 20°C, diluted as
instructed by the supplier. After further washing the alka-
line phosphatase was developed using new fuchsin sub-
strate to give a red colour. Sections were lightly
counterstained using Harris’s haematoxylin or toluidine
blue. Non-immune rat immunoglobulin G was substituted
for the primary antibody at similar concentrations on control
tissue sections [10].
Cell cultures
Rheumatoid synovial tissue and human articular cartilage
were enzymically digested to provide synovial fibroblast
and chondrocyte cultures as previously described [18,19].
Cells were grown in Dulbecco’s Modified Eagle’s
Medium + 10% (vol:vol) foetal calf serum, harvested and
seeded into 12-well culture dishes (Nunc, Gibco, UK)
Triplicate wells of confluent cell cultures in Dulbecco’s
Modified Eagle’s Medium + 2% foetal calf serum were
treated with 1a,25(OH)2D3 (10–8mol/l), IL-1b (0.05ng/ml),
or IL-1b+ 1a,25(OH)2D3  (0.05ng/ml and 10–8mol/l,
respectively) and incubated for 48h at 37°C. The
conditioned medium was collected and assayed for MMP-
1, MMP-2, MMP-3 and MMP-9, and PGE2 using enzyme-
linked immunosorbent assay (ELISA) methodology. Cell
numbers per well were counted at the end of each experi-
ment after 70% ethanol fixation and toluidine blue staining.
Enzyme linked immunosorbent assays
ELISA methodology was used to determine protein levels
of MMP-1 (collagenase 1), MMP-3 (stromelysin) and
MMP-9 (gelatinase B) as previously described [20]. MMP-
2 (Gelatinase A) was measured using ELISA kits pur-chased from The Binding Site (Birmingham, UK); and
PGE2 was measured using an ELISA assay kit purchased
from R & D Systems Europe, Ltd (Abingdon,UK). 
All ELISA results were initially calculated in ng or pg
protein/ml culture medium/106 cells per 48h. Three dif-
ferent cultures of both RSFs and HACs were examined,
but the capacities of each cell type to produce the MMPs
and PGE2 varied between the individual cultures. There-
fore, the data from each culture was ‘normalized’ relative
to control values, and the data sets from the three cultures
of each cell type were subsequently pooled. This provided
an evaluation that showed qualitative similarities for the
RSFs and HACs, but demonstrated differences in
1a,25(OH)2D3 responses by each of these two cell types.
Results
Demonstration of the vitamin D receptor in rheumatoid
tissues in vivo
Specimens of rheumatoid synovial tissue (n=18) immuno-
stained for VDR were shown to have variable distributions
of the receptor. All specimens showed some positive stain-
ing, but this could be less than 5% or as much as 70% of
the total cell population. Different cell types within the
synovial specimens were shown to express the receptor,
including macrophages, endothelial cells, lymphocytes
and fibroblastic cells, but no regular pattern was observed.
Cells with fibroblastic morphology immunostained for
VDR are shown in Figure 1a. Chondrocytes within articu-
lar cartilage from rheumatoid joints also expressed the
receptor in six out of 10 specimens (Fig. 1b), this being a
much higher frequency compared with the one in 10 spec-
imens of normal articular cartilage from nonarthritic joints
(data not shown). VDR-positive cells were also observed
in association with some cartilage–pannus junctions,
described here as the rheumatoid lesion (Fig. 1c).
Effects of 1a a,25-dihydroxyvitamin D3 on matrix
metalloproteinase production by rheumatoid synovial
fibroblasts
1a,25(OH)2D3 alone had no effect on basal MMP produc-
tion by RSFs in monolayer culture, but the simultaneous
addition of 1a,25(OH)2D3 with IL-1b reduced the
expected stimulation of MMP-1, MMP-3 and MMP-9 by
up to 50% (Fig. 2: P=0.096, 0.009 and 0.01, for IL-1b versus
IL-1b + 1a,25(OH)2D3 for MMP-1, MMP-3 and MMP-9,
respectively, by Student’s t-test). MMP-2 production was
not affected by either IL-1b or IL-1b + 1a,25(OH)2D3 (data
not shown), an observation that is in accord with the consti-
tutive nature of MMP-2 expression [21].
Effects of 1a a,25-dihydroxyvitamin D3 on matrix
metalloproteinase production by human articular
chondrocytes
In contrast to the data for RSFs, 1a,25(OH)2D3 had a slight
stimulatory effect on basal production of MMP-1 and
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Figure 1
Immunolocalization of the vitamin D receptor (VDR) in rheumatoid
tissues. (a) Immunolocalization of VDR in rheumatoid synovium. Note
positive red immunostaining of fibroblastic cells. (Counterstain Harris’s
haematoxylin; bar = 25 mm.) (b) Demonstration of VDR in cartilage
from a rheumatoid joint. Note both positive and negative chondrocytes.
(Counterstain Harris’s haematoxylin; bar = 20 mm.) (c) VDR immuno-
localization at the cartilage–pannus junction; cells within both pannus
tissue and cartilage can be seen to be expressing the receptor.
(Counterstain toluidine blue; bar = 25 mm.)MMP-3 by monolayer cultures of HAC (Fig. 3: P=0.098
and 0.002, for control versus 1a,25(OH)2D3, for MMP-1
and MMP-3, respectively, by Student’s t-test). When stim-
ulated with IL-1b MMP-1 and MMP-3 production was
increased, and although simultaneous addition of
1a,25(OH)2D3 had no effect on the stimulation of the
MMP-1 enzyme, MMP-3 production was further enhanced
(Fig 3b: P=0.008, by Students t-test). MMP-9 and MMP-2
were not produced in measurable quantities by these HAC
cultures, either with or without IL-1b stimulation.
Effects of 1a a,25-dihydroxyvitamin D3 on prostaglandin E2
production by rheumatoid synovial fibroblasts and human
articular chondrocytes
PGE2 production by RSFs was unaffected by the addition
of 1a,25(OH)2D3 alone. Treatment of RSFs with IL-1b
upregulated the production of PGE2, but the addition of
1a,25(OH)2D3 together with IL-1b reduced the expected
stimulation of PGE2 almost to control values (Fig. 4a:
http://arthritis-research.com/14oct99/ar0101p01
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Figure 2
The effects of 1a,25-hydroxyvitamin D3 (1,25) on matrix
metalloproteinase (MMP)-1, MMP-3 and MMP-9 production by
rheumatoid synovial fibroblasts (RSFs) after 48 h incubation. (a) MMP-
1 production by RSFs (n = 3) showing normalized values for control; +
1,25 (10–8 mol/l); + interleukin (IL)-1b (0.05 ng/ml); and + IL-1b and
1,25 (0.05 ng/ml and 10–8 mol/l, respectively). Before normalization,
control values for MMP-1 were in the range 50–200 ng/ml culture
medium/106 cells per 48 h. (b) MMP-3 production by RSF (n = 3)
showing normalized values for control; + 1,25; + IL-1b; and + IL-1b
and 1,25. Before normalization, control values for MMP-3 were in the
range 10–40 ng/ml culture medium/106 cells per 48 h. (c) MMP-9
production by RSFs (n = 3) showing normalized values for control;
+ 1,25; + IL-1b; and +IL-1b and 1,25. Before normalization, control
values for MMP-9 were in the range 10–50 ng/ml culture medium/
106 cells per 48 h. Values are shown as means±SEM.
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Figure 3
The effects of 1a,25-hydroxyvitamin D3 (1,25) on matrix
metalloproteinase (MMP)-1 and MMP-3 production by human articular
chondrocytes (HACs) after 48 h incubation. (a) MMP-1 production by
HAC (n = 3) showing normalized data for control; + 1,25 (10–8 mol/l);
+ interleukin (IL)-1b (0.05 ng/ml); and + IL-1b and 1,25 (0.05 ng/ml
and 10–8 mol/l, respectively). Before normalization, control values for
MMP-1 were in the range 50–150 ng/ml culture medium/106 cells per
48 h. (b) MMP-3 production by HAC (n = 3) showing normalized data
for control; + 1,25; + IL-1b; and + IL-1b and 1,25. Before
normalization, control values for MMP-3 were in the range
10–40ng/ml culture medium/106 cells per 48 h. Values are
shown as means±SEM.
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P=0.014, for IL-1b versus IL-1b + 1a,25(OH)2D3, by Stu-
dent’s t-test).
Treatment of HACs with IL-1b also increased the produc-
tion of PGE2, but in contrast to the effects noted for RSFs
this IL-1-stimulation of PGE2 was not affected by the con-
comitant addition of 1a,25(OH)2D3 (Fig. 4b).
To examine the possibility that 1a,25(OH)2D3 might
obscure or interact with the IL-1b receptor of RSFs the
latter were pretreated with 1a,25(OH)2D3 before incuba-
tion with IL-1b. Figure 4c shows that a 1-h preincubation
with 1a,25(OH)2D3 followed by IL-1b was not signifi-
cantly different from the two factors added together, but
preincubation with 1a,25(OH)2D3 for 16 h suppressed the
expected increase in PGE2 production to control values.
This effect was noted even when the 1a,25(OH)2D3 was
removed after the 16 h and IL-1b then added alone (Fig.
4c, data column F). Thus, rather than directly interfering
with the IL-1b receptor, it appears that 1a,25(OH)2D3
reduces the capacity of the RSFs to elaborate PGE2 (and
probably the MMPs shown in Fig. 2) after IL-1b induction.
Discussion
The cell types within the rheumatoid lesion which were
observed to express VDR included chondrocytes,
fibroblasts, macrophages, lymphocytes and endothelial
cells. These cells are all purported to be involved either
directly or indirectly in the degradative processes associ-
ated with rheumatoid arthritis, possibly via their MMP and
prostanoid production, or via the production of mediators
responsible for inflammation and induction of proteinase
expression by other cell types. Thus, the demonstration of
VDR within the rheumatoid lesion provides support for a
functional role of 1a,25(OH)2D3 in rheumatoid arthritis.
MMPs are considered to play important roles in the chon-
drolytic processes of the rheumatoid lesion [14,15,17].
These enzymes are known to be produced by both fibrob-
lasts and chondrocytes, but little has been reported in the
literature regarding a relationship between 1a,25(OH)2D3
and MMP production or its regulation, and most of the data
to date have been obtained from animal studies or immor-
talized cell lines [5–7]. 1a,25(OH)2D3 had little effect on
basal MMP production by RSFs and marginally increased
the basal production of MMP-1 and MMP-3 by chondro-
cytes. More pronounced differences were noted when IL-
1b-stimulated or activated cells were treated with
1a,25(OH)2D3, the RSFs and HACs showing quite dis-
parate responses. These opposite effects may be of rele-
vance to the processes of joint destruction, especially
cartilage loss, because the ability of 1a,25(OH)2D3 to
potentiate MMP-1 and MMP-3 expression by ‘activated’
chondrocytes might facilitate intrinsic cartilage chondrolysis
in vivo. By contrast, the MMP-suppressive effects observed
for 1a,25(OH)2D3 treatment of ‘activated’ synovial fibrob-
Figure 4
The effects of 1a,25-hydroxyvitamin D3 (1,25) on prostaglandin E2
(PGE2) production by rheumatoid synovial fibroblasts (RSFs) and
human articular chondrocytes (HACs) after 48 h incubation. (a) PGE2
production by RSFs (n = 3) showing normalized data for control;
+ 1,25 (10–8 mol/l); + interleukin (IL)-1b (0.05 ng/ml); and + IL-1b and
1,25 (0.05 ng/ml and 10–8 mol/l, respectively). Before normalization,
control values for PGE2 production by RSFs were in the range
500–2000 pg/ml culture medium/106 cells per 48 h. (b) PGE2
production by HACs (n = 3) showing normalized data for control;
+ 1,25; + IL-1b; and + IL-1b and 1,25. Before normalization control
values for PGE2 production by HAC were in the range 100–300 pg/ml
culture medium/106 cells per 48 h. (c) Normalized data for PGE2
production by IL-1b-stimulated RSFs after preincubation with
1a,25(OH)2D3, as follows: A, control; B, +IL-1b; C, 1,25 + IL-1b; D,
1h preincubation with 1,25, then + IL-1b and 1,25; E, 16 h
preincubation with 1,25, then IL-1b + 1,25; F, 16 h preincubation with
1,25, then IL-1b alone. Values are shown as means±SEM.
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Control IL-1 + 1,25 IL-1 1,25lasts might reduce extrinsic chondrolysis and also matrix
degradation within the synovial tissue. We recognize that
the present study is somewhat restricted to the
1a,25(OH)2D3 effects on MMP-1 and MMP-3 production.
Although these are prominent and well characterized
MMPs, there are many other enzymes in this family,
together with plasminogen activators and other proteinases,
which have not been examined. From the disparate effects
of 1a,25(OH)2D3 on the RSFs and HACs it would seem
that further studies on the 1a,25(OH)2D3-modified pro-
teinase phenotypes of these cells are warranted.
Prostaglandins are primary mediators of inflammation and
have important roles in the immune response and the
inflammatory processes associated with rheumatoid arthri-
tis, and PGE2 has been implicated in the potentiation of
MMP production by some cell cultures [22,23].
1a,25(OH)2D3 had little effect on basal PGE2 production
by RSFs, but the enhanced PGE2 production observed
following IL-1b stimulation of these cells was markedly
suppressed by the concomitant addition of 1a,25(OH)2D3.
By contrast, the increased PGE2 production observed for
IL-1b-treated HACs was unaffected by the simultaneous
addition of 1a,25(OH)2D3. Thus, as with MMP produc-
tion, 1a,25(OH)2D3 has disparate effects on IL-1b-stimu-
lated PGE2 production by these two cell types. Different
responses by RSFs and HACs to the same ligand have
been noted before; for example, IL-1b treatment was
shown to stimulate glycosaminoglycan synthesis by RSFs,
but inhibited its production by chondrocytes [24].
In summary, the immunolocalization of VDR in the
rheumatoid lesion has demonstrated that the metabolite
1a,25(OH)2D3 might have a functional role in the
degradative and inflammatory processes of joint disease.
Whereas 1a,25(OH)2D3 does not appear directly to affect
the MMP or prostanoid production by unstimulated RSFs
or HACs in vitro, it was shown to modulate the cytokine-
induced MMP and PGE2 production by these two cell
cultures. The recognized immunomodulatory properties
of 1a,25(OH)2D3 could well be important in rheumatoid
tissues, in which the inflammatory response is a character-
istic feature. The transient, local manifestations of carti-
lage and matrix-degrading activity [25] could be modified
by 1a,25(OH)2D3 if the cells present express VDR and
the metabolite is produced locally. This study has demon-
strated that most rheumatoid synovial specimens were
expressing VDR at the time of surgery, and that IL-1b-
‘activated’ synovial fibroblasts and chondrocytes in vitro
showed significant and different responses to
1a,25(OH)2D3 exposure with regard to MMP and PGE2
production. Such observations suggest that 1a,25(OH)2D3
contributes indirectly rather than directly to MMP regula-
tion via its action on other mediators or their signalling
pathways, in accord with its recognized multifunctional
and immunomodulatory properties [1,7].
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